Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors,Cell Chemical Biology

当前位置： X-MOL 学术 › Cell Chem. Bio. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors
Cell Chemical Biology ( IF 8.6 ) Pub Date : 2017-09-28 00:00:00 , DOI: 10.1016/j.chembiol.2017.08.017
Sherry Niessen , Melissa M. Dix , Sabrina Barbas , Zachary E. Potter , Shuyan Lu , Oleg Brodsky , Simon Planken , Douglas Behenna , Chau Almaden , Ketan S. Gajiwala , Kevin Ryan , RoseAnn Ferre , Michael R. Lazear , Matthew M. Hayward , John C. Kath , Benjamin F. Cravatt

Patients with non-small cell lung cancers that have kinase-activating epidermal growth factor receptor (EGFR) mutations are highly responsive to first- and second-generation EGFR inhibitors. However, these patients often relapse due to a secondary, drug-resistant mutation in EGFR whereby the gatekeeper threonine is converted to methionine (T790M). Several third-generation EGFR inhibitors have been developed that irreversibly inactivate T790M-EGFR while sparing wild-type EGFR, thus reducing epithelium-based toxicities. Using chemical proteomics, we show here that individual T790M-EGFR inhibitors exhibit strikingly distinct off-target profiles in human cells. The FDA-approved drug osimertinib (AZD9291), in particular, was found to covalently modify cathepsins in cell and animal models, which correlated with lysosomal accumulation of the drug. Our findings thus show how chemical proteomics can be used to differentiate covalent kinase inhibitors based on global selectivity profiles in living systems and identify specific off-targets of these inhibitors that may affect drug activity and safety.

更新日期：2017-09-29

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>